In a second update of a systematic review, many new developments in the combined drug treatment of rheumatoid arthritis (RA) are highlighted. In early RA patients, step-down bridge therapy that includes corticosteroids leads to much enhanced efficacy at acceptable or low toxicity. The effects on joint damage may be persistent, but the symptomatic effects are probably dependent on continued corticosteroid dosing. In late patients, cyclosporin improves a suboptimal clinical response to methotrexate, and the triple combination of methotrexate, sulphasalazine and hydroxychloroquine appears to be clinically better than the components. Other combinations are either untested, tested at low sample size, or show negative interaction. In view of the low volume of evidence, most studies need confirmation by replication.
T is a trend among rheumatologists to treat 1997 using the MeSH headings: 'arthritis, rheumatoid'; and 'drug therapy, combination'. The bibliographies rheumatoid arthritis (RA) patients earlier and more aggressively. New scientific evidence supports early of all retrieved articles were scrutinized for additional studies. The first authors of studies published only in intervention with disease-modifying anti-rheumatic drug (DMARD) therapy [1] . Rapid and adequate abstract form were contacted. Such studies were eligible for inclusion if a full manuscript was available. Titles control of disease activity is aimed at the prevention of structural joint damage and subsequent loss of and abstracts (when available) were screened by one author (MB up to August 1992, ACV subsequently) function and quality of life. In this setting, combining so-called DMARDs might lead to additive effects. and any article in English, French, German or Dutch that appeared potentially relevant was retrieved. Alternatively, doses might be reduced, and perhaps some of the toxicity avoided. Many rheumatologists already prescribe combination therapy, although until Study selection and validity assessment recently scientific evidence to support this policy was First, the quality of the studies, and thus the strength lacking. Over the last few years, an increasing number of evidence, was scored on a three-point scale on the of high-quality trials have been published. We present basis of two primary criteria: randomization and blinda second update of a systematic review of combination ing. Accordingly, strong evidence came from randomtherapy in RA [2, 3] . ized, double-blind studies; moderately strong evidence In combining DMARDs, three main strategies can from studies that were randomized, but open or parbe distinguished. In this review, the label 'step-up tially blinded; and weak evidence from all other studies. strategy' is reserved for trials in which patients with This score specified the maximum strength we felt a insufficient clinical benefit from one second-line agent study could yield. A second set of criteria, modified continued the use of this first drug and had another from Sackett et al. [4] was then applied. These were: (or placebo) added to this. The label 'parallel' was (a) adequate outcome assessment (blind and comprisassigned to trials in which the patients started with a ing toxicity); (b) adequate description of study patients combination of new drugs, and 'step-down' to trials (report of at least age and sex, some record on the with sequential withdrawal of simultaneously started previous disease severity and concurrent medication); drugs, prescribed by protocol.
(c) adequate description of the therapeutic manoeuvre (i.e. minimal potential of bias, with blinding, contam-METHODS ination, co-intervention and compliance properly Study identification addressed); (d ) complete accounting of study patients The MEDLINE database was searched from August in the results. To obtain the final quality score, points 1992 (the closing date of the previous review) to July were subtracted for each of these criteria not met. Submitted 26 January 1998; revised version accepted The results of the trials yielding moderately strong 17 February 1998. or strong evidence in the previous reviews (original included baseline patient characteristics, study and the interval between August 1992 and July 1997, yielded 231 new citations. Together with previous concomitant treatment, outcome measures, and details on toxicity, withdrawals and eligibility criteria for reviews, this brings the total to 611 titles scanned, 100 were retrieved and 18 selected for review. Of the disease activity.
Data extraction and analysis
Clinical efficacy, i.e. improvement in clinical outcome screened abstracts and titles, 38 were linked to a possibly relevant article. Three articles in Japanese measures, was compared between the combinedtreatment group and the single-treatment group. In the [27] [28] [29] were not rated. Not selected articles were case reports, editorials, observational or non-randomized case of more than one control group, comparisons were made between the combined-treatment group and studies. Three studies that described adjuvant treatment with oral corticosteroids, androgens and oestroeach control group, but eventually the comparison with the best performing control group was decisive.
gens, respectively, were not included because they failed to meet the criterion of a one-type single The WHO/ILAR core set measures assessed efficacy [5] . These measures comprise tender and swollen joint DMARD control group [30] [31] [32] . Two studies described an extended follow-up or radiological assesscount (or a score), pain assessment, patient and physician (or observer) global assessment, physical function ments of an already selected article [33, 34] ; the data from these publications were added to those of the index [here, in every case Health Assessment Questionnaire (HAQ) or a modification thereof ], and original study [19, 20] . Two articles were found in the reference list of selected articles [9, 10] . Four possibly acute-phase reaction [i.e. erythrocyte sedimentation rate ( ESR) or C-reactive protein (CRP)]. When less relevant reports in abstract form were found in abstract book supplements. The corresponding manuscripts of than four of these measures had been assessed, first grip strength and second morning stiffness were two recently published articles were obtained [21, 22] . The total of 20 (six old, 14 new) included trials are selected as well. Four levels of efficacy were distinguished based on differences in improvement in the listed in Table I . The total number of patients included in these trials is 1952. All trials used a more or less selected measures: strict criterion to verify the presence of active disease. $ combined treatment 'substantially more effective'
The studies are ranked according to treatment strategy ('++' in the summary table): significantly greater as well as the DMARDs of choice. Six studies describe improvement in the combined-treatment group in at a step-up strategy; two of these used cyclosporin, three least half of the selected measures (minimum two used i.m. gold as anchor drug, and two methotrexate. out of four), plus improvement of at least 150%
Ten studies describe a parallel strategy; of these, six that of the control group; used methotrexate (all but one as anchor drug), six $ combined treatment 'more effective' ('+'): significstudies used antimalarials (one as anchor drug), three antly greater improvement in at least half of the used sulphasalazine, one i.m. gold, dapsone or -selected measures; penicillamine (as anchor drugs); also used were aurano-$ 'positive trend' ('+?'): significantly greater improvefin and azathioprine (as additional drug; total more ment in at least 25% of the measures, or significantly than 10, due to combinations). The studies with a stepgreater improvement only in a predefined summary down strategy (four in total ) all used steroids [i.m. index of measures; methylprednisone pulses or predniso( lo)ne orally]. $ 'no difference' ('='): the remainder.
Steroids were added to i.m. gold (in two studies) or When the total number of core set measures (plus sulphasalazine (also in two studies; in one study predgrip strength and morning stiffness) was less than nisolone was added together with methotrexate). four, only trends were scored.
Toxicity was rated as increased ('+') when significStudies with step-up strategy Smyth et al. [6 ] added 75 mg/day cyclophosphamide antly more patients from the combined-treatment group were withdrawn from the study medication or placebo to a stable and continued pre-trial dose of prednisone varying between 3 and 15 mg/day in 29 because of adverse events. Likewise, it was rated as decreased ('−') when significantly less patients from patients with established disease. After 6 months, outcomes in the combined-treatment group were significthe combined-treatment group were withdrawn from the study medication because of adverse events. A antly more improved in grip strength and an inflammatory index comprising swelling, redness, pain significant difference (or trend ) in numbers of adverse events not leading to withdrawal was rated as 'trend on motion, heat and tenderness, but not in ESR. Only one case of alopecia was reported in the combinedof more toxicity' ('+?') or 'trend of less toxicity' ('−?'). Where possible, results of statistical tests comparing treatment group with no withdrawal due to toxicity in either group. Given the paucity of outcomes, this the effect or toxicity of the different treatments were calculated or recalculated using the reported data.
suggests a trend of increased efficacy with no increase in toxicity, but the disease activity at baseline was less RESULTS in the placebo group. Moreland et al.
[7] performed a dose-finding study Previous work had yielded eight relevant studies [2, 3] . Six of these eight provided 'strong' or 'moderately of monoclonal anti-CD4 antibody cM-T412 in three different doses or placebo added to stable treatment strong evidence' and are included in the final selection [6, 12, 14, 20, 24, 26 ] . The current search, covering with methotrexate (∏ 15 mg/week) in 64 patients with Step-up Step-down Results from comparisons with two control groups are separated by a semicolon (;). Behind the slash (/) is the total number of assessed core set measures. NB. The efficacy rating is derived from the O score, and in some cases also from improvement in two non-core set measures (grip strength and morning stiffness) or from improvement in a predefined primary outcome index. AU, i.m. gold salts; AUR, auranofin; AZA, azathoprine; Buc, bucillamine; aCD4, monoclonal anti-CD4 antibodies (three doses); Cq, chloroquine; CyA, cyclosporin; CyP, cyclophosphamide; Daps, dapsone; Dpen, -penicillamine; Hcq, hydroxychloroquine; MP, methylprednisone pulses; MTX, methotrexate; Pred, prednisone; Predl, prednisolone; SSZ, sulphasalazine.
*Non-core set measures of patient's and (non-blind) clinician's assessment of overall efficacy did show significantly more improvement in the combined-treatment group. †The combined-treatment group showed significantly better scores for a validated disease activity index based on five variables in a flow chart. ‡Low sulphasalazine doses in the combined-treatment groups: 1 g/day. §Low methylprednisone doses: 5 mg/kg/pulse.
refractory RA. Assessments after 3 months treatment combined-treatment group, although this did not reach significance. The total withdrawal rate was high: 42%. and 4 i.v. pulses of anti-CD4 did not show any relevant between-group difference in clinical efficacy or toxicity.
The authors report that toxicity might be enhanced as 18 patients in the combined-treatment group vs 10 in Tugwell et al. [8] added cyclosporin or placebo to methotrexate in 148 patients with established disease the control group were withdrawn for adverse effects. Faarvang et al. [13] compared the combination of and insufficient response to methotrexate alone. After 6 months, all outcomes with the exception of ESR sulphasalazine and hydroxychloroquine with each of these agents alone in 91 patients. Analysis of study were substantially and significantly better in the combined-treatment group (HAQ and global assessments completers after 6 months treatment showed no difference between combined treatment and single sulpha-P < 0.001). Expressed in percentages, improvement as compared with placebo varied between 19 and 26%. salazine treatment. However, combined treatment did show better outcomes in swollen joint count and The frequency of adverse effects was similar to prior trials of methotrexate and cyclosporin used alone. A patient's global assessment compared to hydroxychloroquine alone (P < 0.05). In our view, this only confirms threshold of 30% increase in serum creatinine for dose reduction resulted in a relatively low mean cyclosporin that sulphasalazine is a more effective drug than hydroxychloroquine. Both groups showed similar progresdose (3 mg/kg). Eighty per cent of the included patients had stable co-medication with low-dose sion of joint damage on radiographs. Withdrawal, for adverse effects as well as other reasons, in this trial corticosteroids (∏10 mg).
Bendix and Bjelle [9] added cyclosporin or placebo was frequent in all treatment groups (32%). Gibson et al. [14] compared the combination of -to i.m. gold treatment in 40 patients. After 6 months the combined treatment showed increased efficacy only penicillamine and chloroquine in comparison with each of these alone in 72 patients. After 12 months, the in patient's global assessments of overall health and clinical efficacy, and non-blind assessments by a treatdecreases in ESR in the combined-treatment group were significantly larger compared to chloroquine, but ing physician (P < 0.01 and <0.05); other core set measures, including blinded observer's global assessnot compared to -penicillamine. Improvements in morning stiffness, joint tenderness and swollen joint ment, showed no difference. No serious adverse effects were noted. Higher blood pressure and signs of renal score and grip strength did not show significant contrasts between treatment groups. There were significfunction impairment were found more often in the cyclosporin-treated group, also dose reduction was antly more adverse effects in the combined-treatment and the -penicillamine groups compared with required significantly more often in the cyclosporin group. Adverse events requiring symptomatic treatchloroquine. Haar et al. [15] compared the combination of ment occurred only in eight patients; four in each treatment group. Six months after the end of combinahydroxychloroquine and dapsone with each of these drugs alone in 80 patients. After 6 months of treatment, tion therapy, all differences had disappeared. Yasuda et al. [10] added bucillamine, a drug the combination showed a positive trend with a significant difference only in one measure: ESR, but the developed in Japan, or placebo to i.m. gold treatment in 24 patients. After 3 months, the combined-treatment baseline values for ESR were also better in this treatment group. Patients treated with combined dapsone group had significantly better outcomes in swollen joint count, physician's global assessment and CRP and hydroxychloroquine showed less progression of joint damage, but this result was weakened by (P < 0.05), and similar outcomes (trend ) in tender joint count and ESR. Withdrawal for lack of efficacy serious disbalance between groups in baseline values. Withdrawals for toxicity were more numerous in the only occurred in the control group (five patients), and withdrawal due to toxicity occurred more often in the combined-treatment group, but this difference was not significant (8 vs 3 and 4; P = 0.11). combined-treatment group (5 vs 3).
Porter et al.
[11] added hydroxychloroquine or plaTrnavsky et al.
[16 ] compared the combination of hydroxychloroquine and methotrexate with hydroxycebo to i.m. gold treatment in 142 patients. After 6 months, no differences were evident between the chloroquine and placebo in 40 patients. After 6 months, the combined treatment showed a positive trend with groups. Withdrawal (for all reasons) was comparable in both trial groups (~28%). Owing to the lack of significantly better outcomes in two of five core set measures; patient's global assessment and ESR description of previous medication and patient compliance, the strength of evidence was rated as moderate.
(P < 0.05). The combined-treatment group contained more patients without progression of joint damage, but the report allows no conclusion on whether this Studies with parallel strategy Scott et al. [12] also tested the combination hydroxydifference was significant. Withdrawal for adverse effects was rare (one case). chloroquine and i.m. gold, but in a parallel strategy against i.m. gold alone in 101 patients. After 12 months Ferraz et al. [17] compared the combination of methotrexate and chloroquine to methotrexate alone of treatment, the combination showed a positive trend in all of the outcomes, but only CRP (P = 0.01) and in 82 patients. After 6 months, the combination was more effective in tender joint count (P = 0.04) and the a priori defined composed summary index of disease activity were significantly better (P < 0.05). There was HAQ (P = 0.04). The authors state that combined treatment was slightly more toxic (and effective), less progression of joint damage on radiographs in the although only three patients were withdrawn due to less radiographic progression in the methotrexate group. Adverse effects occurred primarily in the comadverse effects (two of whom had combined treatment). The percentage loss to follow-up (partially bined-treatment and azathioprine group (trend ). Numbers of withdrawn patients per treatment group related to non-compliance) was quite high (9%) in this study.
due to toxicity are not available, but therapeutic interventions related to adverse events were reported more O'Dell et al. [18] compared the combination of methotrexate, sulphasalazine and hydroxychloroquine often in the combined treatment group (48% vs 25% and 21%). to the combination of sulphasalazine and hydroxychloroquine, and to methotrexate alone, in 102
Haagsma et al. [21] compared the combination of methotrexate and sulphasalazine with each of these patients. The dose of sulphasalazine (1 g/day) was low. Every 3 months, dose adjustments of methotrexate drugs alone in 105 patients. After 52 weeks, the combination was not more effective in any of the four core were allowed, guided by assessments of the effect of therapy. The main assessment of efficacy was after 9 set or other measures. Response to treatment was exceptionally good in all groups: 74% met the preliminmonths when no further opportunity was offered to adjust the methotrexate dose in case of insufficient ary ACR criteria for improvement [36 ] . Fewer patients were withdrawn for toxicity reasons in the single therapy response (by definition <50% improvement in modified Paulus criteria). At this time, 27/31, 23/35 methotrexate treatment group compared to the combined-treatment group (P = 0.025). In contrast with and 28/36 patients were considered responders ( x2 test: triple therapy vs sulphasalazine-hydroxychloroquine most other trials, the patients included in this study had early disease. These results agree with those of a P = 0.04; vs methotrexate P = 0.32; overall P = 0.12). Based on survival analyses, the authors report significtrial only published in abstract form [37] , but contrast with the results of an open trial (not included in this antly more patients with a response to triple therapy after 9 months and conclude that triple therapy results review) in which patients with insufficient reaction to sulphasalazine first stopped this drug and afterwards in enhanced efficacy with no increase in toxicity. Nonresponders were considered therapy failures and furwere randomized to combined methotrexate-sulphasalazine, or methotrexate alone. Here, the combinedther report on follow-up was restricted to responders. At 9 months of follow-up and according to the rules treatment group showed significantly better outcomes [38] . of this review, triple therapy only showed a positive trend: significantly better swollen and tender joint counts compared to methotrexate, and significantly Studies with step-down strategy Boers et al. [22] compared the combination of better swollen joint count and ESR compared to hydroxychloroquine-sulphasalazine. At 2 yr follow-up sulphasalazine (2 g/day), methotrexate (7.5 mg/week) and prednisolone (initially 60 mg/day, tapered in 6 (with 38% patients still in follow-up), the betweentreatment group contrasts were larger (and highly weekly steps to 7.5 mg/day) with sulphasalazine alone in 155 patients. The last assessment of therapy effect significant), but this concerns only the patients who had a sufficient response according to the modified of combined treatment was at week 28 of follow-up as prednisolone and methotrexate were tapered and Paulus criteria at month 9. Withdrawal for toxicity was rare at year 2, but data on withdrawals due to stopped after 28 and 40 weeks, respectively. At week 28, significantly better outcomes in the combinedadverse events at month 9 were not available; however, overall withdrawal at month 9 was about equal. treatment group were seen in all composite measures and all but one of the core set measures (P < 0.002). Williams et al. [19] compared the combination of methotrexate and oral gold (n = 106) against treatment In these measures, the improvement in the combinedtreatment group was 2-fold or almost 2-fold that of with each of these agents alone in 335 patients. After 48 weeks, none of the five assessed core set measures the single sulphasalazine group. Seventy-two per cent of the patients in the combined-treatment group vs showed more benefit in the combined-treatment group. Withdrawals for toxicity occurred somewhat more 49% in the sulphasalazine group had improved according to the ACR criteria (P = 0.006). The clinical frequently in the combined-treatment group (21% vs 15% and 14%; trend, not significant). Subsequently, difference between the groups decreased and was no longer significant after prednisolone was stopped, and Lopez-Mendez et al. [33] reported no differences between the groups in progression of radiographic there were no further changes after methotrexate was stopped. Withdrawal for toxicity during the first 28 scores at week 48. Willkens et al. [20] compared the combination of weeks was significantly less in the combined-treatment group (1 vs 7; P = 0.04). The frequency of adverse methotrexate and azathioprine with each of these drugs alone in 209 patients. Data on ESR and HAQ were events not resulting in withdrawal was similar in both groups. In addition to the clinical results, progression subsequently added in a letter [35] , and data on 48 weeks of follow-up and radiological progression were of joint damage in the combined-treatment group was one-third that in the sulphasalazine group. This effect published later [34] . The combination was not better in the between-group comparisons (withdrawals conpersisted until week 80, i.e. 1 yr after the withdrawal of prednisolone which started at week 28 of follow-up. sidered as treatment failures), except for ESR when combined treatment was compared to single azathio- Van Gestel et al. [23] compared the combination of i.m. gold (50 mg/week) and prednisone (initially prine (P = 0.03). The authors also report a trend of 10 mg/day for 12 weeks, then tapered to zero in 2-weekly steps) with i.m. gold alone in 40 patients. The main assessment was at week 12, just before prednisone was gradually withdrawn. At this time, all five assessed core set measures showed significantly greater improvement in the combined-treatment group; the magnitude of this improvement is not reported. The improvement in a composite index, the disease activity score (DAS) [39] , in the combined-treatment group was more than 2-fold that with single gold treatment. Progression of joint damage was similar in both groups. Withdrawal due to toxicity was the same in both groups after 20 weeks (four patients in each group). The authors report troublesome rebound effects in the combined-treatment group after withdrawal of prednisone. This appears to be based on a single significant between-group comparison in an array of 13: in week 20 of follow-up, the DAS in the combined-treatment group was worse than in the control group. However, at this moment (and up to week 44), patients in both groups were still better than at baseline. After 44 weeks (32 weeks after the beginning of tapering prednisone), no between-group difference F. 1.-Three-dimensional summary of the efficacy of combination remained.
therapy. From the perspective of the five most frequently used drugs, Corkill et al. [24] Withdrawal due to toxicity during 24 weeks was more frequent in the combined-treatment group, but not significantly so.
with corticosteroids appears safe and, in the right dose and duration, truly disease modifying; however, the Finally, Ciconelli et al. [25] compared the addition of three low-dose i.v. methylprednisone pulses effect on disease activity (not damage) appears to be dependent on continuation of low-dose corticosteroids. (5 mg/kg), at baseline, month 1 and 2, with sulphasalazine alone in 38 patients. Eighty per cent of the patients This strengthens Kirwan et al.'s [30] finding of the damage control resulting from corticosteroid adjuvant in both groups had a prescription of oral corticosteroids. In the 6 month study period, no differences therapy, a study not included in this review because anti-rheumatic therapy was not uniformly applied in between treatment groups in efficacy or toxicity were found. The relatively low dose of methylprednisone in the control group. In late disease, patients with a suboptimal response to methotrexate improve clinically a population already treated with corticosteroids may have decreased the possible contrast. This important with cyclosporin, and some patients on triple therapy with methotrexate, sulphasalazine and hydroxychloroco-intervention with oral corticosteroids was the reason to rate the strength of evidence from this trial as quine appear clinically better off than patients on a two-drug combination or methotrexate alone. This lifts moderate. Figure 1 summarizes the heterogeneity of the findthe gloom from the other studies compiled so far, where negative interaction (i.e. results of the combinaings of this systematic review graphically. Except for corticosteroids, there appears to be no trend for an tion are the same or only slightly better than the single drugs) prevails, often at the cost of somewhat increased overall beneficial effect of a particular drug in a combination. The figure also shows the lack of data: low toxicity. Interestingly enough, rheumatologists have not waited for these first positive results or heeded the sample size in most trials, and many untested combinations. many negative trials; according to two recent surveys published in abstract [40, 41] , they almost universally DISCUSSION embrace combination therapy. Felson et al. [42] recently published a meta-analysis In its second update since 1991, this review highlights exciting new developments in the combined drug treaton combination therapy in which he pooled the available data. He found a negative answer to the question: ment of RA. In early disease, step-down bridge therapy rheumatic drugs; a randomized, controlled trial. Ann 'Does combination therapy on average make a differ- Intern Med 1996; 124:699-707. ence compared to average single therapy?' In our view, 2. Boers M, Ramsden M. Long-acting drug combinations the heterogeneity in combinations, strategies and in rheumatoid arthritis: a formal overview. J Rheumatol patient material makes this a less interesting research 1991;18:316-24. question. As shown in Fig. 1, each type II errors can be minimized by sufficiently large Arthritis Rheum 1995; 38:1581-8. sample sizes. In practice, it is often hard to find eligible 
